{
  "id": "e4ce4da954c1f212",
  "title": "STAT+: Insmed basks in the success of its lung disease drug \u2014 and prepares for what\u2019s next",
  "description": "Insmed's CEO said months ago that the commercial opportunity for the biotech's newly approved lung disease drug was \"huge.\" He was right.",
  "content": "Insmed's CEO said months ago that the commercial opportunity for the biotech's newly approved lung disease drug was \"huge.\" He was right.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2026/01/12/jpm-conference-insmed-brinsupri-bronchiectasis/?utm_campaign=rss",
  "published_at": "2026-01-12T13:57:48+00:00",
  "fetched_at": "2026-01-13T00:20:01.657666+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "drug",
    "ai"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: Insmed basks in the success of its lung disease drug \u2014 and prepares for what\u2019s next",
    "description": "Insmed's CEO said months ago that the commercial opportunity for the biotech's newly approved lung disease drug was \"huge.\" He was right.",
    "url": "https://www.statnews.com/2026/01/12/jpm-conference-insmed-brinsupri-bronchiectasis/?utm_campaign=rss",
    "published": "2026-01-12T13:57:48+00:00",
    "source": "STAT"
  }
}